GLP-1 drugs linked to major slowdown in breast cancer, prostate cancer and more: new study
A new study suggests that GLP-1 weight-loss drugs may significantly slow the progression of certain obesity-related cancers. Conducted by the Cleveland Clinic, the research indicates that patients using GLP-1 medications experienced lower rates of cancer progression compared to those on other diabetes drugs. The findings, which will be presented at the 2026 ASCO Annual Meeting, highlight the potential of GLP-1 pathways in influencing cancer growth and spread.
- ▪The study included 12,112 patients with various obesity-related cancers.
- ▪Patients taking GLP-1 drugs had significantly lower progression to stage 4 disease for four types of cancers.
- ▪The most notable risk reduction was observed in non-small cell lung cancer at 50%.
Opening excerpt (first ~120 words) tap to expand
Health GLP-1 drugs linked to major slowdown in breast cancer, prostate cancer and more: new study By Melissa Rudy, Fox News Published May 28, 2026, 11:03 a.m. ET See more of our coverage in your search results. Add The New York Post on Google Originally Published by: Tick bite ER visits hit highest seasonal level in years as doctors warn of disease surge Sleep doctor reveals the brutal health downside of daylight saving time Doctors push new blood tests for colon cancer as cases surge in younger adults Popular glucagon-like peptide-1 (GLP-1) weight-loss drugs may help slow the spread of some cancers, according to new research to be presented at a major medical conference.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at New York Post.
Discussion
0 commentsMore from New York Post
